A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder.

Abstract

Results of a randomized prospective study are reported in which mitomycin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients with primary or recurrent pTa and pT1 bladder tumors, including carcinoma in situ. The followup (or time in study) varied from 2 to 81 months (mean 36 months). After complete transurethral resection of all visible tumors the patients were treated with 30 mg. mitomycin C once a week for 4 consecutive weeks and thereafter every month for a total of 6 months, and 5 x 10(8) colony-forming units Tice BCG or RIVM-BCG once a week for 6 consecutive weeks. For papillary tumors mitomycin C and RIVM-BCG treatments were equally effective (p = 0.53), and mitomycin C was more effective than Tice BCG therapy (p = 0.01).

2 Figures and Tables

0100200300'99'01'03'05'07'09'11'13'15'17
Citations per Year

434 Citations

Semantic Scholar estimates that this publication has 434 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Vegt1995ARS, title={A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder.}, author={P. D. J. Vegt and Johannes Alfred Witjes and Wim P. J. Witjes and Wim H. Doesburg and Frans M. J. Debruyne and Adrian P M van der Meijden}, journal={The Journal of urology}, year={1995}, volume={153 3 Pt 2}, pages={929-33} }